Scalable Measurements of Intrinsic Excitability in Human iPS Cell-Derived Excitatory Neurons Using All-Optical Electrophysiology.


Journal

Neurochemical research
ISSN: 1573-6903
Titre abrégé: Neurochem Res
Pays: United States
ID NLM: 7613461

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 02 05 2018
accepted: 04 12 2018
revised: 02 12 2018
pubmed: 4 1 2019
medline: 8 5 2019
entrez: 4 1 2019
Statut: ppublish

Résumé

Induced pluripotent stem (iPS) cells offer the exciting opportunity for modeling neurological disorders in vitro in the context of a human genetic background. While significant progress has been made in advancing the use of iPS cell-based disease models, there remains an unmet need to characterize the electrophysiological profile of individual neurons with sufficient throughput to enable statistically robust assessment of disease phenotypes and pharmacological modulation. Here, we describe the Optopatch platform technology that utilizes optogenetics to both stimulate and record action potentials (APs) from human iPS cell-derived excitatory neurons with similar information content to manual patch clamp electrophysiology, but with ~  3 orders of magnitude greater throughput. Cortical excitatory neurons were produced using the NGN2 transcriptional programming approach and cultured in the presence of rodent glial cells. Characterization of the neuronal preparations using immunocytochemistry and qRT-PCR assays reveals an enrichment of neuronal and glutamatergic markers as well as select ion channels. We demonstrate the scale of our intrinsic cellular excitability assay using pharmacological assessment with select ion channel modulators quinidine and retigabine, by measuring changes in both spike timing and waveform properties. The Optopatch platform in human iPS cell-derived cortical excitatory neurons has the potential for detailed phenotype and pharmacology evaluation, which can serve as the basis of cellular disease model exploration for drug discovery and phenotypic screening efforts.

Identifiants

pubmed: 30603979
doi: 10.1007/s11064-018-2694-5
pii: 10.1007/s11064-018-2694-5
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

714-725

Références

Br J Pharmacol. 1976 Jun;57(2):163-84
pubmed: 1084773
Cell Stem Cell. 2008 Dec 4;3(6):637-48
pubmed: 19041780
Nat Biotechnol. 2011 Mar;29(3):279-86
pubmed: 21293464
Nat Rev Drug Discov. 2011 Jun 24;10(7):507-19
pubmed: 21701501
Cell Stem Cell. 2013 May 2;12(5):559-72
pubmed: 23642365
Neuron. 2013 Jun 5;78(5):785-98
pubmed: 23764284
Nat Neurosci. 2013 Jul;16(7):780-9
pubmed: 23799470
Ann Neurol. 2013 Jul;74(1):128-39
pubmed: 23821540
Drug Discov Today. 2013 Nov;18(21-22):1067-73
pubmed: 23850704
Curr Med Chem. 2014;21(6):722-54
pubmed: 24251563
PLoS Biol. 2014 Jan;12(1):e1001757
pubmed: 24409097
Am J Psychiatry. 2014 Apr;171(4):395-7
pubmed: 24687194
Cell Rep. 2014 Apr 10;7(1):1-11
pubmed: 24703839
Nat Methods. 2014 Aug;11(8):825-33
pubmed: 24952910
Nat Rev Drug Discov. 2014 Aug;13(8):577-87
pubmed: 25033734
Neuron. 2014 Nov 5;84(3):546-53
pubmed: 25442933
Neuron. 2014 Nov 5;84(3):554-63
pubmed: 25442934
Biol Psychiatry. 2015 May 1;77(9):775-84
pubmed: 25534755
Trends Cogn Sci. 2015 Apr;19(4):183-7
pubmed: 25727774
Eur Neuropsychopharmacol. 2015 May;25(5):599-656
pubmed: 25836356
Cell Stem Cell. 2015 Sep 3;17(3):316-28
pubmed: 26279266
Nat Med. 2015 Sep;21(9):979-88
pubmed: 26340119
Nature. 2015 Nov 5;527(7576):95-9
pubmed: 26524527
Methods. 2016 May 15;101:27-35
pubmed: 26525194
Mol Cell Neurosci. 2016 Jun;73:52-62
pubmed: 26655799
Mol Cell Neurosci. 2016 Jun;73:96-103
pubmed: 26777134
Nat Rev Mol Cell Biol. 2016 Mar;17(3):170-82
pubmed: 26818440
Mol Cell Neurosci. 2016 Jun;73:104-15
pubmed: 26826498
Neuropharmacology. 2017 Jul 1;120:11-19
pubmed: 26979921
Nature. 2016 May 5;533(7601):125-9
pubmed: 27120160
Cold Spring Harb Perspect Med. 2016 Jul 01;6(7):
pubmed: 27371672
Prog Neurobiol. 2017 May;152:3-20
pubmed: 27519538
Nat Neurosci. 2016 Oct 26;19(11):1392-1396
pubmed: 27786187
Nat Rev Drug Discov. 2016 Nov 29;15(12):813-814
pubmed: 27895328
Expert Opin Drug Discov. 2017 Jul;12(7):673-686
pubmed: 28521526
Biochem Pharmacol. 2017 Nov 1;143:10-24
pubmed: 28522405
Drug Discov Today Technol. 2017 Mar;23:17-25
pubmed: 28647082
Curr Protoc Pharmacol. 2017 Sep 11;78:11.20.1-11.20.24
pubmed: 28892145
Br J Pharmacol. 2017 Dec;174 Suppl 1:S160-S194
pubmed: 29055033
Biomed Opt Express. 2017 Nov 29;8(12):5794-5813
pubmed: 29296505

Auteurs

Luis A Williams (LA)

Q-State Biosciences, 179 Sidney Street, Cambridge, MA, 02139, USA.

Vaibhav Joshi (V)

Q-State Biosciences, 179 Sidney Street, Cambridge, MA, 02139, USA.

Michael Murphy (M)

Q-State Biosciences, 179 Sidney Street, Cambridge, MA, 02139, USA.

John Ferrante (J)

Q-State Biosciences, 179 Sidney Street, Cambridge, MA, 02139, USA.

Christopher A Werley (CA)

Q-State Biosciences, 179 Sidney Street, Cambridge, MA, 02139, USA.

Theodore Brookings (T)

Q-State Biosciences, 179 Sidney Street, Cambridge, MA, 02139, USA.

Owen McManus (O)

Q-State Biosciences, 179 Sidney Street, Cambridge, MA, 02139, USA.

Johannes Grosse (J)

Takeda California, San Diego, USA.

Ceri H Davies (CH)

Takeda Pharmaceuticals Company Limited, Shonan Health Innovation Park, 26-1 Muraoka Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan. ceri.davies@takeda.com.

Graham T Dempsey (GT)

Q-State Biosciences, 179 Sidney Street, Cambridge, MA, 02139, USA. graham.dempsey@qstatebio.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH